KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Share-based Compensation (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Share-based Compensation for 8 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 14.9% year-over-year to $2.4 million, compared with a TTM value of $9.9 million through Dec 2025, down 17.7%, and an annual FY2025 reading of $9.9 million, down 17.7% over the prior year.
  • Share-based Compensation was $2.4 million for Q4 2025 at Esperion Therapeutics, up from $2.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $8.6 million in Q2 2021 and bottomed at $2.3 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $3.7 million, with a median of $3.1 million recorded in 2023.
  • The sharpest move saw Share-based Compensation rose 16.08% in 2021, then plummeted 58.91% in 2022.
  • Year by year, Share-based Compensation stood at $4.5 million in 2021, then fell by 16.96% to $3.7 million in 2022, then decreased by 21.4% to $2.9 million in 2023, then dropped by 3.94% to $2.8 million in 2024, then fell by 14.9% to $2.4 million in 2025.
  • Business Quant data shows Share-based Compensation for ESPR at $2.4 million in Q4 2025, $2.3 million in Q3 2025, and $2.7 million in Q2 2025.